Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2026-03-01 @ 1:49 AM
Study NCT ID:
NCT02110394
Status:
COMPLETED
Last Update Posted:
2016-07-06
First Post:
2014-04-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia
Sponsor:
Astellas Pharma Europe B.V.
Organization:
Study Overview
Official Title:
Observational Program for Evaluation of Ribomustin Use in the First Line Therapy of Chronic Lymphocytic Leukemia
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NORMA
Brief Summary:
Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the first line therapy of chronic lymphocytic leukemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: